Depression drug from Contineum and J&J fails in mid-stage study

Phase 2negativePIPE-307Negative

AI Analysis

Summary

Contineum Therapeutics and Johnson & Johnson's oral M1 receptor inhibitor PIPE-307 (JNJ-5120) failed to meet primary endpoints in a mid-stage study for major depressive disorder, marking the second Phase 2 failure for this program within a year.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Failed to meet primary endpoints in mid-stage study in major depressive disorder

Importance:7/10

Sentiment:

-0.90

Clinical Trial FailurePhase 2PsychiatryM1 receptor inhibitorNegative Data

Related Companies

$JNJ

Read the original article

Published by Endpoints News on September 15, 2026 10:29 AM

Read Original